Inhibition of thyrotropin and prolactin secretions in primary hypothyroidism by 2-Br-alpha-ergocryptine.
D000284:Administration, Oral; D000328:Adult; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology; D007037:Hypothyroidism / Q000503:physiopathology*; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013997:Time Factors
D004876:Ergot Alkaloids; D011388:Prolactin; D013972:Thyrotropin